Every material Form 8-K Biomea Fusion, Inc. has filed with the SEC since May 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 13, 2026, Biomea Fusion reported topline Phase 1 GLP-131 results for BMF-650, its investigational oral GLP-1 receptor agonist. In Cohorts 1-4, mean Day 29 weight reduction ranged from 1.5% to 3.2% versus 0.1% for pooled placebo, and the company reported no severe or serious adverse events among active-dose participants, but the results are preliminary, the sample sizes are small, and the company says longer-term toxicology studies are still needed before further development, which may include a partnership.
Cohorts 1-4 (outpatient): mean Day 29 weight reduction of 1.5% to 3.2% versus 0.1% for pooled placebo.
Cohort 5 (under confinement, 200 mg then 400 mg): 6.1% (6.2 kg) mean weight reduction at Day 29; the company says it should be interpreted separately because confinement appeared to affect eating behavior.
No severe or serious TEAEs, TEAE-related dose modifications, or TEAE-related discontinuations across the 40 active-dose MAD participants; nausea occurred in 17.5% and vomiting in 7.5% across active cohorts.
Longer-term toxicology studies are required; the company is positioning BMF-650 for a strategic partnership, which could include licensing, while its primary focus remains icovamenib.
Biomea Fusion updated the expected timing of topline results from its ongoing Phase I GLP-131 trial of BMF-650 in obese, otherwise healthy volunteers, now expected in October 2026. The filing does not disclose any trial data, and the change is a timing update only.
Topline results from the Phase I GLP-131 trial of BMF-650 are now expected in October 2026.
The trial enrolls obese, otherwise healthy volunteers.
The update was announced on September 22, 2026, in a Form 8-K filed under Item 8.01 Other Events.
Biomea Fusion reported a first-quarter 2026 net loss of $12.4 million, down from $29.3 million a year earlier, as research and development and general and administrative expenses fell. Cash, cash equivalents and restricted cash were $45.1 million at March 31, 2026, down from $56.2 million at December 31, 2025, and the company said its cash runway extends into the first quarter of 2027.
Net loss attributable to common stockholders was $12.4 million, or $0.17 per share, versus $29.3 million, or $0.80 per share, in Q1 2025.
R&D expenses were $9.1 million versus $22.9 million; G&A expenses were $3.7 million versus $6.8 million.
Cash, cash equivalents and restricted cash were $45.1 million at March 31, 2026, versus $56.2 million at December 31, 2025.
Cash runway is projected into the first quarter of 2027; initial 28-day weight reduction data for BMF-650 is expected in Q2 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Biomea Fusion, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →